369656-57-5

Basic information

• Product Name: 8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI)
• Synonyms: 8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI);8-quinolinamine,5,6,7,8-tetrahydro-,(8s)-;(8S)-5,6,7,8-Tetrahydro-quinolin-8-ylamine;(8S)-5,6,7,8-Tetrahydro-8-quinolinamine;(S)-(+)-8-Amino-5,6,7,8-tetrahydroquinoline;(S)-5,6,7,8-Tetrahydroquinolin-8-aMine;(S)-5,6,7,8-Tetrahydro-quinolin-8-ylamine;(8S)-5,6,7,8-tetrahydroquinolin-8-amine
• CAS NO: 369656-57-5
• Molecular Formula: C₉H₁₂N₂
• Molecular Weight: 148.21
• Product Categories: PYRIDINE;AMINEPRIMARY;Quinoline Derivertives
• Mol File: 369656-57-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 277.3 °C at 760 mmHg
• Flash Point: 146 °C
• Appearance: /
• Density: 1.081 g/cm³
• Vapor Pressure: 0.00456mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.93±0.20(Predicted)
• CAS DataBase Reference: 8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI)(369656-57-5)
• EPA Substance Registry System: 8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI)(369656-57-5)

Safety Data

• Hazardous Substances Data: 369656-57-5(Hazardous Substances Data)

Usage

General Description

8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI) is a chemical compound with the molecular formula C9H11N. It is a derivative of quinoline and exists in the form of a white to off-white crystalline powder. 8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI) is used in various chemical and pharmaceutical applications, including as an intermediate in the synthesis of other organic compounds. It is also known for its potential biological and pharmacological activities. However, the specific properties and potential uses of 8-Quinolinamine,5,6,7,8-tetrahydro-,(8S)-(9CI) may vary depending on the specific isomer and its stereochemistry.

InChI:InChI=1/C9H12N2/c10-8-5-1-3-7-4-2-6-11-9(7)8/h2,4,6,8H,1,3,5,10H2/t8-/m0/s1

Upstream product

• 502612-64-8 (8S)-N-{(1S)-1-[4-(methyloxy)phenyl]ethyl}-5,6,7,8-tetrahydro-8-quinolinamine 
• 1431726-92-9 (S)-8-amino-5,6,7,8-tetrahydroquinoline hydrochloride 
• 451466-64-1 (R)-5,6,7,8-tetrahydroquinolin-8-yl acetate 
• 451466-81-2 (R)-8-hydroxy-5,6,7,8-tetrahydroquinoline 
• 14631-46-0 5,6,7,8-tetrahydroquinoline-8-ol 
• 298181-83-6 5,6,7,8-tetrahydroquinolin-8-yl amine 
• 141-78-6 ethyl acetate 
• 451466-68-5 (S)-8-azido-5,6,7,8-tetrahydroquinoline 

Downstream Products

• 558444-72-7 (S)-2-[4-(5,6,7,8-tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione 

Relevant articles and documents

Monofunctional PtII Complexes Based on 8-Aminoquinoline: Synthesis and Pharmacological Characterization

Among the heterocyclic compounds, 8-aminoquinoline and its derivatives have become important candidates for the preparation of new antiproliferative metallo-drugs. Here, we reported the synthesis and cytotoxicity evaluation of a series of platinum complexes using 8-aminoquinoline and its chiral 5,6,7,8-tetrahydro-derivatives as chelating ligands. In the proposed complexes, a differently and opportunely alkylated imidazole was used to prepare the corresponding monofunctional platinum complexes. The preliminary cytotoxicity evaluation was carried out on the highly aggressive MDA-MB-231, invasive and poorly differentiated triple-negative breast cancer (TNBC) cell line, furnishing a significant IC50 10.9 ± 1.3 μM for Pt-IV. This series of complexes revealed an induction of p53, interfering with the progression of the G0/G1 phase of the cell cycle.

CHEMICAL COMPOUNDS

The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.

CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND

To provide novel nitrogen-containing compounds having antagonism to CXCR4 and remedies for disease, such as rheumatism, cancer metastasis, etc., based on the CXCR4 antagonism. Nitrogen-containing compounds represented by the following general formula and